Absci Q3 2023 Earnings Report

Absci EPS Results

• Actual EPS: -$0.24
• Consensus EPS: -$0.23
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Absci Revenue Results

• Actual Revenue: $0.74 million
• Expected Revenue: $3.01 million
• Beat/Miss: Missed by -$2.27 million
• YoY Revenue Growth: N/A

Absci Announcement Details

• Quarter: Q3 2023
• Date: 11/14/2023
• Time: N/A
• Conference Call Date: Tuesday, November 14, 2023
• Conference Call Time: 7:00AM ET

Absci (NASDAQ:ABSI) (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework. By integrating AI-driven protein design with advanced screening processes, the company seeks to rapidly advance promising biologic candidates from concept through lead optimization. Absci’s platform supports research in areas such as oncology, immunology and metabolic disease, providing partners with drug-like protein candidates and data insights that can de-risk preclinical development.

Founded in 2018 and headquartered in Seattle, Washington, Absci maintains collaborative relationships with multiple global pharmaceutical organizations and operates additional research facilities in the United States. The company’s leadership team brings together experts in protein engineering, data science and drug development, aiming to transform biologics discovery through technological innovation. As Absci continues to expand its pipeline partnerships and platform capabilities, it remains focused on delivering scalable solutions for the next generation of protein therapeutics.